HubSpot (HUBS): Reassessing Valuation After a Sharp Pullback in Share Price

HubSpot (HUBS) has quietly drifted lower this year, even as revenue and earnings grow at a healthy clip. With the stock down sharply from earlier highs, investors are reassessing what this CRM leader is really worth.

See our latest analysis for HubSpot.

At around $387.58 per share, HubSpot’s 90 day share price return of minus 24.47 percent and year to date share price return of minus 44.43 percent show momentum clearly fading, even though the three year total shareholder return of 31.51 percent still points to longer term value creation.

If HubSpot’s recent slide has you reassessing your watchlist, this could be a good moment to discover other tech names using our high growth tech and AI stocks.

With revenue still growing double digits and Wall Street targets sitting far above today’s price, investors now face a key question: is HubSpot quietly slipping into undervalued territory, or is the market already baking in its future growth?

Advertisement

Most Popular Narrative: 33.1% Undervalued

With HubSpot last closing at $387.58 against a widely followed fair value near $580, the narrative leans toward meaningful upside if its growth path holds.

Ongoing movement upmarket into larger enterprise customers, combined with a seat-based pricing model and cross-sell of premium platform capabilities (Core Seat, Smart CRM), is leading to larger deals and higher gross margins, which should boost earnings power as operating leverage increases.

Read the complete narrative.

Curious how this move upmarket turns a fast growing yet lightly profitable platform into a high margin compounder, and which aggressive revenue and margin bridges make that $580 fair value add up?

Result: Fair Value of $579.55 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this upside view could unravel if AI disrupts HubSpot’s core SEO driven funnel, or if macro pressure forces SMB and mid market clients to cut spend.

Find out about the key risks to this HubSpot narrative.

Build Your Own HubSpot Narrative

If you see HubSpot’s story differently, or would rather dig into the numbers yourself, you can build a custom view in minutes: Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding HubSpot.

Looking for more investment ideas?

Before the next move in HubSpot’s share price, put yourself in front of the market by lining up fresh, data driven opportunities with our powerful stock screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if HubSpot might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:HUBS

HubSpot

Provides a cloud-based customer relationship management (CRM) platform for businesses in the Americas, Europe, and the Asia Pacific.

Flawless balance sheet with high growth potential.

Advertisement

Weekly Picks

CE
Ceazar
SPAI logo
Ceazar on Sparc AI ·

When GPS fails: this small cap is fixing a $54B drone problem

Fair Value:CA$5.2554.7% undervalued
112 users have followed this narrative
0 users have commented on this narrative
24 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4859.0% undervalued
214 users have followed this narrative
8 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43047.7% undervalued
20 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9953.6% undervalued
26 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

AS
AstrisCorporateAdvisory
3132 logo
AstrisCorporateAdvisory on Macnica Holdings ·

Core business remains firm, new growth initiative delayed

Fair Value:JP¥2.61k19.7% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DI
divine_4y1uv
AIIO logo
divine_4y1uv on Robo.ai ·

Robo.ai Appoints Former INTERPOL President H.E. Dr. Ahmed Naser Al-Raisi as Chairman of Its Subsidiary Alif Holding

Fair Value:US$541.6% undervalued
1 users have followed this narrative
2 users have commented on this narrative
0 users have liked this narrative
BE
PRCT logo
Betsareoff on PROCEPT BioRobotics ·

PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin

Fair Value:US$25.2629.2% undervalued
4 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28032.1% undervalued
211 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.0% undervalued
97 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6510.2% undervalued
74 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0